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progression- free survival after 14 days of
targeted therapy in metastatic renal cell
carcinoma
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Anders Ullén2 and Per Sandström2Abstract
Background: To determine whether changes in the metabolism of metastatic renal cell carcinoma (mRCC)
assessed by F18-FDG-PET after 14 and 28 days of treatment with tyrosine kinase inhibitors can predict overall
and progression- free patient survival.
Methods: Thirty-nine consecutive patients with mRCC were included prospectively and underwent PET
examinations prior to and after 14 and 28 days of standard treatment with sunitinib (n = 18), sorafenib (n = 19)
or pazopanib (n = 2). The PET response was analyzed in terms of SUVmax, SULpeak, and total lesion glycolysis
and a positive response (defined as a 30% reduction) compared to overall and progression- free survival.
Results: Thirty-five patients with at least one metabolically active metastatic lesion prior to treatment underwent
additional FDG-PET examinations after 14 (n = 32) and/or 28 days (n = 30) of treatment. Changes in either SULpeak or
total lesion glycolysis were correlated to both progression-free and overall survival (for TLG2.5 responders, HR = 0.38
(95% CI: 0.18-0.83) and 0.22 (95% CI: 0.09-0.53), and for TLG50 responders, HR = 0.25 (0.10-0.62) and 0.25 (95% CI:
0.11-0.57) and for SULpeak responders, HR = 0.39 (95% CI: 0.17-0.91) and 0.38 (95% CI: 0.15-0.93), respectively).
In contrast SUVmax response did not predict progression- free or overall survival (HR = 0.43 (95% CI: 0.18-1.01)
and 0.50 (95% CI: 0.21-1.19), respectively).
Conclusions: Assessment of early changes in SULpeak and total lesion glycolysis undergoing treatment with tyrosine
kinase inhibitors by FDG-PET can possibly predict progression- free and overall survival in patients with mRCC.
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In the last decade, new antiangiogenic therapies such as
the tyrosine kinase inhibitors (TKIs) sunitinib, sorafenib
and pazopanib [1-3] have changed the management of
patients with metastatic renal cell carcinoma (mRCC).
Eventually all patients experience relapse and the dur-
ation of the drug response varies widely with certain
patients receiving little benefit. Traditional assessment* Correspondence: jacob.farnebo@ki.se
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unless otherwise stated.of drug response with computed tomography has limi-
tations in the case of mRCC, since metastases often
enter a period of dormancy and tumor shrinkage occurs
only after a cascade of cellular and subcellular changes [4].
Thus, novel biomarkers of response are required to allow
early consideration of alternative treatment for non-
responders as well as to reduce unnecessary side-effects
and costs.
Positron emission tomography (PET) employing 18
F-flouro-deoxyglucose (FDG) allows detection and sta-
ging of many cancers, revealing early changes in tumor
metabolism that might be valuable biomarkers for drug
response [5]. A recent investigation using this techniquel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dicted progression-free survival (PFS) in patients with
mRCC [6], but a similar study could only predict overall
survival (OS) [7] after 4 months treatment. In both cases
the maximal standardized uptake (SUVmax) was the sole
FDG-PET parameter utilized as an indicator of meta-
bolism. Although SUVmax, the highest uptake of FDG
in one voxel (image volume) of the tumor, is indeed
most often used in clinical practice, several other PET-
parameters are being explored [8]; including metabolic
tumor volume (MTV), total lesion glycolysis (TLG) and
peak standardized uptake normalized to lean body mass
(SULpeak).
Here, the hypothesis that alterations in the uptake of
FDG by mRCC after only 14 days of treatment correlates
both with progression-free and overall survival was
tested. We also predicted that the manner in which this
uptake is measured plays a critical role in assessment of
the metabolic response.
Methods
Thirty-nine selected patients with metastatic renal cell
carcinoma who were scheduled to start treatment with
sorafenib, sunitinib or pazopanib at the Karolinska
University Hospital (Stockholm, Sweden) or Uppsala
University Hospital (Uppsala, Sweden) between April
2006 and December 2010 agreed to participate in this
study. Written informed consent was obtained from all
patients. Their baseline characteristics are documented
in Table 1. Approval was obtained from the Stockholm
Regional Ethical Review Board (2007/1551-31/3).
Treatment
Following a baseline PET scan, 18 patients were treated
with sunitinib, 19 with sorafenib and two with pazopanib.Table 1 The baseline characteristics of the 39 participants
Mean age (years) 65












Chemotherapy 116 of those in the sunitinib group had had no prior treat-
ment while one patient had already received interferon-
alpha and one other had received gemcitabine. Among
those treated with sorafenib two had had no prior treat-
ment, while 11 received sunitinib, 5 interferon-alpha and
one both interferon-alpha and sunitinib. Neither patient
administered pazopanib had received prior treatment.
One patient entered the study twice, initially receiving
sunitinib and later sorafenib. All treatment was admin-
istered in accordance with the recommendations: in the
case of sunitinib a starting dose of 50 mg once daily for
four week periods separated by two weeks off treatment;
for those receiving sorafenib, a starting dose of 400 mg
twice daily; and for pazopanib a dose of 800 mg once daily.
Decisions concerning treatment were based on standard
anatomic assessment of response by CT and evaluated
according to RECIST1.1 [9]. The PET assessments did
not influence these decisions but the treating physician
was not blinded to the PET results.
PET examinations
PET examinations were carried out (immediately prior
to and after 14 and 28 days of treatment) using the
standard clinical protocol. The first 5 patients (included
during 2006 and 2007) were examined with a ECAT
EXACT 31 PET camera (CTI, Knoxville, Tenn., USA) and
30 of the subsequent patients with a Biograph 64 True-
point PET/CT (Siemens Medical Solutions, Erlangen
Germany) scanner (during 2008–2011). In the case of two
patients from Uppsala University Hospital Discovery
ST PET/CT scanner (GE Healthcare) was employed. For
each patient all three scans were performed on the same
machine.
One hour after intravenous injection of 4 MBq FDG/kg
the patients were scanned from the base of their skulls
to the proximal aspects of the thighs. They were
instructed to fast for at least 6 hours prior to examin-
ation and the blood level of glucose was measured rou-
tinely. In addition, a low-dose attenuation correction
and a full-dose diagnostic CT were performed. Contrast
medium was injected intravenously in connection with
the baseline and third scan. Assessment was acheived
with Siemens True-D Syngo software.
Image analysis
All PET scans were analyzed retrospectively by the
same radiologist (JF or PG), who had received no infor-
mation concerning either the clinical or radiological
outcome. Metastatic lesions were identified by correlating
focal uptake of FDG with the corresponding CT images,
with correction for normal physiological uptake. A two-
dimensional circle drawn around the metastatic lesion in
the transverse plane allowed the software to plot a three-
dimensional metabolic volume. Manual adjustment in the
Table 2 Univariate analysis of clinical parameters
observed in connection with the baseline FDG-PET that
were associatied with overall survival
HR (95% CI)
The hottest lesion: high SUVmaxa 3.56(1.63-7.76)*
The hottest lesion: high SULpeaka 2.67(1.22-5.84)*
The hottest lesion: high TLG50a 2.45(1.14-5.27)*
The hottest lesion: high TLG2.5a 1.74(0.83-3.63)
Rating of Heng factor: 1 versus 2 and 3 0.33(0.11-0.96)*
ECOG performance status: 0 versus 1 and 2 1.94(0.91-4.14)
Pretreatment: yes versus none 1.57(0.75-3.27)
aComparing above and below median value.
* = Statiscially significant.
Farnebo et al. BMC Cancer 2014, 14:408 Page 3 of 8
http://www.biomedcentral.com/1471-2407/14/408cranio-caudal plane was occasionally required to exclude
uptake by normal proximate tissue. For semi-quantitative
analysis of FDG uptake, the SUVmax was identified. The
metabolic tumor volume (MTV) was defined as an iso-
contour along either 50% of SUVmax or a fixed SUV
threshold of 2.5 within a three-dimensional region of
interest (ROI). For assessment of total lesion glycolysis
(TLG), the average SUV within the tumor lesion was
multiplied by its MTV to obtain TLG50 and TLG2.5,
respectively.
For assessment according to PERCIST1.0 [10], all SUV
values were normalized to lean body mass (SUL). A
sphere ROI with a volume of one cubic centimeter was
drawn around the region of the tumor demonstrating
most rapid uptake of FDG and the average uptake within
that volume defined as SULpeak.
Assessment of the metabolic response
For comparison, the metabolic response was assessed in
different ways. Metastatic lesions that avidly took up
FDG were identified from the baseline scan and this
uptake evaluated on the basis of SUVmax, SULpeak,
TLG50 and TLG2.5. No more than five lesions in total
and two lesions per organ were examined in each
patient. The sum of the uptake by these target lesions at
baseline and the percentage change after 14 and 28 days
of treatment were calculated. In a parallel analysis, the
lesion that took up FDG the most rapidly (hottest lesion)
at baseline was evaluated on its own.
Metabolic response was defined as a 30% reduction in
either SUVmax, TLG50 or TLG2.5. Metabolic progres-
sion was defined as the appearance of new metabolic
active lesions typical this type of cancer and/or at least a
30% increase in SUVmax, TLG50 or TLG2.5 in compari-
son to baseline. When neither progression nor regres-
sion was observed, the tumor was considered to be
metabolically stable.
For assessment according to the PERCIST 1.0 criteria
[10], a greater reduction than 30% in SULpeak was de-
fined as partial metabolic response (PMR). Progressive
metabolic disease (PMD) was defined as the appearance
of new metabolic lesions or an increase in the SULpeak
of more than 30% and/or in TLG50 of more than 75%.
Once again, the SULpeak of both the hottest lesion
alone and of all target lesions combined were analyzed.
Assessment of the clinical outcome
The patients were followed-up 3, 5, 7 and 9 months after
initiation of treatment or earlier if clinically indicated.
Assessment of the anatomic response with CT was car-
ried out using RECIST 1.1 [9]. The time to progression
was calculated as the period from date of the baseline
scan to the detection of progressive disease by CT.
Overall survival was calculated from the date of thebaseline scan to death or to the date of the final follow-
up (patients still alive are displayed as censored cases
in the Kaplan-Meier survival graphs).
Statistical analyses
Overall survival and progression-free survival were
analyzed with the Kaplan-Meier procedure, and the
log-rank test applied for statistical comparison of inde-
pendent subgroups. Univariate Cox proportional hazard
analysis with 95% confidence intervals was employed to
evaluate the impact of baseline characteristics on over-
all survival (Table 2) as well as the association between
metabolic PET response and overall survival. The differ-
ence between pre- and post therapeutic measurements
was calculated as continuous variables and by percent-
age change. Hazard ratios were provided. Statistical




Of the 39 patients who underwent a FDG-PET scan
prior to treatment, four patients exhibited no metabo-
lically active lesions and were therefore excluded from
further evaluation. Four had lesions that avidly took up
FDG but did not fulfill the PERCIST1.0 criteria for
measurable target lesions. Four remained alive at the
time of the final follow-up (September 2012) and all the
others had died from metastatic disease. The median
progression-free and overall survival was 159 days (range
14–1153 days) and 652 days (range 42–2310 days),
respectively. The median survival of the censored
patients was 1629 days (range 1280–2683) and the
reverse Kaplan-Meier estimate of the median follow-
up 1467 days (95% CI: 966–1967 days).
Results of the baseline PET scan
The median time between the baseline PET examination
and initiation of treatment was 2.5 days (range 0–14).
Table 3 The number of patients demonstrating a metabolic response following 14 and 28 days of treatment
After 14 days After 28 days
Metabolic response Metabolic progress Metabolic response Metabolic progress
SULpeaka 9/28 8/28 11/28 4/28
SUVmax 8/32 5/32 12/30 6/30
TLG2.5 14/32 6/32 14/30 6/30
TLG50 15/32 3/32 12/30 5/30
HottestSULpeaka 9/28 7/28 10/28 5/28
HottestSUVmax 8/32 4/32 8/30 4/30
HottestTLG2.5 14/32 6/32 14/30 6/30
HottestTLG50 17/32 5/32 15/30 6/30
aAssessed according to PERCIST1.0. Only 28 patients had a lesion that fulfilled the PERCIST criteria.
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FDG at baseline was 2.3 (median 2, range 1–5) and for the
hottest lesion, SUVmax ranged from 2.6-25.3 (median
7.1), SULpeak from 2.1-16.1 (median 4.6), TLG50 from
6–1128 (median 58) and TLG2.5 from 3–5511 (median
115). Univariate analysis of the hottest lesion revealed that
SUVmax, SULpeak and TLG50 values above the median
were significantly correlated both with shorter PFS (not
shown) and OS (Table 2). Heng score (good versus poor)
at baseline was associated with overall survival but there
was no association between ECOG status or previous
treatment and overall survival (Table 2).
Metabolic response following 14 days of treatment
Thirty-two patients underwent a PET scan after a median
of 14 days (range 10–17) of treatment, with determination
of SULpeak in 28 and of TLG50 and TLG2.5 in all 32 par-
ticipants. Metabolic response and progress after 14 days of
treatment are displayed in Tables 3, 4 and Figure 1. On
the basis of total lesion glycolysis as reflected in TLG50
and TLG2.5, more of the patients were responders or
demonstrated metabolic progress than indicated by the
SUVmax. Metabolic response indicated by SULpeak,














aAccording to PERCIST1.0, * = Significant within a confidence interval of 95%.overall survival and PFS (Figures 1, 2 and Table 4), while
there was no significant association between the SUVmax
response and overall survival (Table 4). In analyses of the
hottest lesions SULpeak TLG2.5 and TLG50 demon-
strated significant associations (Table 4).
Analysis of the intermediate group according to the
Heng classification [11] revealed that patients whose
TLG2.5 did not respond had a significantly poorer prog-
nosis than responders (Figure 2A). In a separate analysis
of patients who had received no pre-treatment, meta-
bolic response was significantly associated with overall
survival (Figure 2B).
Metabolic response following 28 days of treatment
Thirty patients conducted a PET-scan after 28 days of
treatment (median 27, range 20–76). Three patients
conducted only a baseline and a 28 day PET and five
patients conducted only a baseline and a 14 day PET.
Metabolic response and progress after 28 days of treat-
ment are displayed in Tables 3, 4 and Figure 1.
Discussion
To our knowledge this is the first demonstration that
















Figure 1 The metabolic response of patients with mRCC after 14 days treatment with tyrosine kinase inhibitors. (A) Waterfall plots of
the metabolic response of patients with mRCC after 14 days of treatment with tyrosine kinase inhibitors as reflected in SULpeak, TLG75 and
TLG50. Kaplan-meier graphs comparing responders and non-responders with regards to time to progression (B) and overall survival (C).
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only 14 days of treatment with a tyrosine kinase inhibi-
tor. Previous reports have either failed to predict out-
come [7] or have involved evaluation at later timepoints
[6,12,13]. Present findings highlight the value of volume-
based metabolic parameters (such as SULpeak and TLG)
in assessing the response of patients with mRCC by
FDG-PET.
In line with previous reports (5, 6), SUVmax failed to
predict outcome after 14 and 28 days of treatment. A
possible explanation could be that SUVmax only reflectsa single voxel subjected to a highly variable degree of
noise [14], and is thus less reliable for detecting subtle
metabolic changes. Recently, SULpeak has been recom-
mended as a more robust alternative. Indeed we found
here that the response in SULpeak was more closely
correlated to clinical outcome than the change in SUV-
max. One problem associated with the use of SULpeak
is how to define the region of interest, the choice of
which can influence the value obtained substantially
[15]. The volumetric thresholds of SUV 2.5 and 50% of
SUVmax were selected here after an initial analysis of
AB
Figure 2 Kaplan-Meier survival curves comparing subgroups of
patients. (A) Comparing the subgroup of patients with an
intermediate prognostic Heng factor score and (B) the group of
patients with no previous treatment, on the basis of metabolic
response or lack of metabolic response (metabolic stable disease
and metabolic progress) to 14 days of treatment with tyrosine
kinase inhibitors as reflected in TLG2.5.
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90% of SUVmax). Use of a too low threshold sometimes
resulted in too much background interference and unreal-
istic large tumor volume. On the other hand a too high
threshold led to an unnecessary reduction of the metabolic
volume of the tumor. We observed a significant correl-
ation between either the MTV or TLG response and
clinical outcome, with TLG appearing to be more com-
pelling, since this parameter contains more information
about the of FDG-uptake. Comparison of analyses of
the hottest lesion and multiple lesions revealed that the
association with clinical outcome was stronger when
several lesions were analyzed.Among several studies of monitoring treatment with
FDG-PET published during the past 20 years, a con-
sistent finding has been that this approach allows more
accurate differentiation between treatment induced
fibrosis/necrosis and viable tumor tissue. In malignant
lymphoma [16,17], FDG-PET now plays a central role
in defining tumor response. In patients whose gastro-
intestinal stromal tumors were treated with imatinib,
the FDG-PET response after only 1 week of treatment
(which is much sooner than anatomic changes are
expected) proved to be a valuable predictor of long-
term outcome [18]. In addition, contrast-enhanced
ultrasound was able to detect responses in patients
with mRCC after only 15 days of sunitinib treatment
and to successfully associate these responses with
clinical outcome [19] indicating that the therapeutic
activity starts early. Our present findings following
14 days of treatment thus confirm these earlier ones.
Furthermore, our observations indicate that elevated
uptake of FDG in metastatic lesions prior to com-
mencement of treatment correlates with poor prog-
nosis as shown previously [7].
This study has several limitations. The number of
examined patients was relatively small, thus a multiva-
riate analysis could not be performed. The first five
patients included were examined with older PET equip-
ment (i.e. not with integrated PET/CT) and two patients
underwent PET/CT at a different hospital. Although we
do not believe that this was likely to influence the out-
come. Our ambition was to examine all of the patients
on the 14th day of treatment, but this was not always
feasible. Four patients did not undergo all three scans
for various reasons. Patients were treated with agents
with different kinase inhibitory profiles, which could
possibly have affected the PET outcome profiles. The
agents used in this study are all potent inhibitors of
VEGFR-2, but it is not known how this and other vari-
ous biophysical properties impact on FDG-uptake. All of
the patients administered sunitinib had received no prior
treatment, whereas most of our patients treated with
sorafenib received this as second-line therapy, which
might have affected their susceptibility to TKI treatment.
Still, in our separate analysis of patients with no previous
treatment, there was an association between metabolic
response and overall survival. Metabolic response was
arbitrary defined as 30% reduction and progression as
30% increase/or new lesion in PET signal. Some patients
experienced borderline increase/decrease in PET signal
putting them in different response groups despite small
differences. Thus, the number of metabolic responders/
progressors in the univariate analysis sometimes vary
in between groups. We can provide no other reason
for this limited concordance. Nonetheless, the PET
response for SULpeak, TLG2.5 and TLG50 observed
Farnebo et al. BMC Cancer 2014, 14:408 Page 7 of 8
http://www.biomedcentral.com/1471-2407/14/408independently, demonstrated a statistically significant
association with patient outcome.
It remains somewhat unclear how to define metabolic
response of mRCC with PET. The European Organization
for Research and Treatment of Cancer (EORTC) [20]
defines partial metabolic response as a decline of SUV
of more than 25%. This definition does not take into
account which SUV value should be analyzed, the size
of the region of interest, the optimal cut-off limits for
SUV or the number of lesions that should be analyzed.
The proposed PERCIST classification is one attempt to
establish more robust PET assessment of response and
there are other alternatives which include total lesion
glycolysis and metabolic volume of the tumor.
Conclusion
This study indicates that FDG-PET can be used to assess
the response of metastatic renal cell cancer to tyrosine
kinase inhibitors after only 14 days of treatment. We
demonstrate the importance of volumetric PET-response
parameters SULpeak, TLG50 and TLG2.5, and propose
these parameters as surrogate indicators of PFS and OS
for prospective validation in a larger cohort.
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